Depending on the cutoff definition (140/90 or 130/90), Hypertension (HTN) affects 30 to 46% of the population. Based on attributable risk, it causes 18% of the heart attacks, 35% of the strokes, 39% of heart failure in men and 59% of heart failure in women and 23% of renal failure. It contributes to 500,000 deaths each year from cardiovascular disease. It costs $76 Billion dollars of the $351 Billion we spend yearly on cardiovascular disease. The average cost is $1,048/hypertensive/year and that is expected to triple in the next 10 years. It consumes 42 million office visits per year. Despite its high prevalence, significant morbidity and mortality, and excessive cost, it is poorly managed. If successfully managed, $1,048 per hypertensive per year could be saved in cardiovascular disease costs. A pilot study of the A4M system completed in 2019 showed a 75% reduction in provider management time and improvement in the blood pressure rate of control from 0% to 58% in patients with documented resistant hypertension and 76% in office based “uncontrolled HTN”.
You are paying too much for white coat HTN and getting too little from a trial-and-error system that delivers inferior results; 48.3%, less than a coin toss. Furthermore, you are missing masked HTN that will harm your patients and increase CV disease costs in the future. The ROI for payers using the A4M system is estimated to be over 20:1. The reduced provider time management more than pays for the system once fully implemented into your EMR. Let us show you....
We are looking for early adopters to participate in pilot studies of up to 2,000 patients per pilot. The minimum support fee is $20,000 per month for a six- month pilot program. This includes video seminars, in person seminars, grand rounds, and educational materials on how to manage HTN and use the software. If we do not improve your rate of control over your baseline rate of control, we would refund $80,000 of the $120,000. Your risk is capped at $6,666 per month.